Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
MindBio Therapeutics logo — Advancing mental health treatments. Multiple Phase 2B clinic...

MindBio Therapeutics

Advancing mental health treatments. Multiple Phase 2B clinical trials underway. Publicly listed on CSE:MBIO FRA:WF6.

Founded 2021 Australia Melbourne, Australia 4 employees Pharmaceutical

General Information

Company Name MindBio Therapeutics
Founded Year 2021
Location Australia Melbourne, Australia +1
Employees 4
Industries Pharmaceutical
Social

Get notified when MindBio Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MindBio Therapeutics

MindBio Therapeutics is a clinical stage drug development company based in Australia, pioneering psychedelic microdosing in multiple Phase 2B clinical trials. Their lead candidate drug, MB22001, is a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for safe take-home microdosing, with ongoing Phase 2 clinical trials. These trials include Phase 2B studies in patients with Major Depressive Disorder and those with Late Stage Cancer and Depression. The Phase 2B trial in patients with Major Depressive Disorder aims to evaluate the effectiveness of MB22001 in treating depression. In an open label Phase 2A trial, 53% of patients with depression were in complete remission at week 8. This promising result, with a 60% overall improvement in depressive symptoms, provides confidence for the ongoing Phase 2B trials. Additionally, the Phase 2 clinical trials for cancer patients will assess the feasibility of conducting a randomized controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard treatment, providing initial indications of potential benefits of psychedelic microdosing in advanced cancer. With its innovative approach and promising results, MindBio Therapeutics is positioned as a key player in the pharmaceutical industry. Founded in 2021, the company represents an intriguing investment opportunity due to its pioneering work in mental health research and Phase 1 & 2A trials completion.

Taxonomy: mental health research, psychedelic medicines, drug development, Phase 2B trials, Major Depressive Disorder, late stage cancer, LSD microdosing, clinical trials, psychotherapy, anxiety, depression, meaning-centred psychotherapy, cancer patients, drug formulation, mindfulness

No funding data available for MindBio Therapeutics yet.

Get notified when MindBio Therapeutics raises funding

MindBio Therapeutics Alternatives & Competitors

MindBio Therapeutics vs
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. Canada

A neuroscience-focused biopharmaceutical company

Post Ipo Equity
333 employees
Biopharma, Biotechnology

FAQ About MindBio Therapeutics

Advancing mental health treatments. Multiple Phase 2B clinical trials underway. Publicly listed on CSE:MBIO FRA:WF6.
MindBio Therapeutics was founded in 2021.
MindBio Therapeutics is headquartered in Melbourne, Australia.
MindBio Therapeutics operates in the following industries: Pharmaceutical.
MindBio Therapeutics has approximately 4 employees.
Top alternatives and competitors to MindBio Therapeutics include Xenon Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MindBio Therapeutics and Xenon Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MindBio Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy